TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CardioSideral Heart Surgery: Randomized Study on Sucrosomial Iron Supplementation Before Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Undergoing elective Heart Surgery -~Exclusion Criteria:~- Emergent or Urgent Indication

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CardioSIDERAL (Type: EXPERIMENTAL): Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Massage Therapy to Induce Sleep in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* \> 3 days old~* 32-48 weeks adjusted gestational age~* Minimum of 28 weeks gestational age at birth~* Clinically stable as determined by an neonatologist~* Stable respiratory status on room air or nasal cannula flow \<2 LPM~* Not meeting exclusion criteria~Exclusion Criteria:~* Documented maternal opiate use prior to admission to Labor and Delivery (opiates administered by physicians' order during labor prior to delivery do not mandate exclusion from the study as long as the mother does not have a past history of opiate abuse or a positive drug screen at hospital admission prior to delivery).~* Clinically unstable and/or unable to be moved from the infant warmer~* Severe congenital anomalies likely to be associated with developmental delay~* Apgar score of ≤ 3 at 5 minutes of age~* Any other condition that in the opinion of the investigator might result in unnecessary or excessive risk to the subject~* Unstable respiratory status~* Sedation in the previous 24 hours before the infant's trial.~* Neurological disease: grade III or IV intraventricular hemorrhage, periventricular leukomalacia, evidence of hypoxic ischemic encephalopathy~* Anticipated painful procedures during the study period between 9 am and 12 pm

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 20 Weeks
- Healthy Volunteers: f

Study Arms:
- Massage therapy (Type: EXPERIMENTAL): Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
- No massage therapy (Type: NO_INTERVENTION): This was a crossover trial with two arms. On one day, infants received massage therapy for 10 minutes. On the other day, infants were monitored as usual with the Actigraph to measure sleep efficiency, but received no massage therapy. This was the control or no intervention arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adenosine Cardioplegia; Improved Cardioprotection?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective patients~* Ejection fraction \> 40%~* Age 40-75~* No release og TnT or CKMB within last week before CABG~* Pure CABG~Exclusion Criteria:~* Age \>75 or \< 40~* EF \< 40%~* Emergency operations~* Unstable angina~* Release of TnT or CKMB within the week before operation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Adenosine cardioplegia (Type: EXPERIMENTAL): Adenosine cardioplegia
- Control (Type: ACTIVE_COMPARATOR): Standard hyperkalemic cardioplegia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Patient with histologically-confirmed, locally advanced or metastatic tumor who has progressed on standard therapy or for whom no standard therapy exists, with the following restriction:~   * Part I: solid tumors of any origin;~  * Part II: breast, gastric, urothelial and endometrial tumors;~2. For Part II: HER2 tumor status as defined in the protocol;~3. ECOG performance status ≤ 1;~4. Life expectancy \> 12 weeks;~5. Adequate organ function;~6. For Part II: measurable disease.~Main Exclusion Criteria:~1. Anthracycline treatment within 3 months and/or abnormal cardiac biomarker values;~2. Other anticancer therapy (except for LHRH agonists) within 4 weeks (6 weeks for nitrosoureas and mitomycin C);~3. History of infusion-related reactions and/or hypersensitivity to trastuzumab or (ado-) trastuzumab emtansine;~4. Severe, uncontrolled systemic disease;~5. LVEF \< 55%, or a history of absolute decrease in LVEF of ≥ 10% points to \< 50% during previous treatment with trastuzumab or (ado-)trastuzumab emtansine, or a history of decrease in LVEF to \< 40% during previous treatment with trastuzumab or (ado-)trastuzumab emtansine;~6. History of clinically significant CV disease;~7. Symptomatic brain metastasis, or therapy for brain metastasis (excluding PCI and dexamethasone treatment with stable or decreasing daily dose) within 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYD985 (trastuzumab vc-seco-DUBA) (Type: EXPERIMENTAL): HER2-targeting Antibody-Drug Conjugate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Parts A and B~Inclusion Criteria:~* Diagnosis of AIP~* Urine PBG at Screening indicating patient is a high excreter~* No clinically significant health concerns~* Women of child bearing potential must have a negative pregnancy test, not be nursing, and use effective contraception~* Willing to provide written informed consent and willing to comply with study requirements.~Exclusion Criteria:~* Porphyria attack within 6 months of screening~* Started a new prescription medication within 3 months of screening~* Clinically significant abnormal laboratory results~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection~Part C~Inclusion Criteria:~* Diagnosis of AIP~* Patient experienced a porphyria attack or was taking medication to prevent attacks recently~* No clinically significant health concerns~* Women of child bearing potential must have a negative pregnancy test, not be nursing, and use effective contraception~* Willing to provide written informed consent and willing to comply with study requirements.~Exclusion Criteria:~* Stared a new prescription medication within 3 months of screening~* Clinically significant abnormal laboratory results~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- givosiran (ALN-AS1) (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adipose Tissue Extract and Platelet-rich Plasma Use for Wound Healing

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* donor site indication~Exclusion Criteria:~* immunosupressive states~* terminal renal insufficiency~* pregnancy~* coagulation dyscrasias~* active infection in donor site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CONTROL (Type: NO_INTERVENTION): No intervention
- ADIPOSE TISSUE EXTRACT (Type: EXPERIMENTAL): Adipose Tissue extract application
- PLATELET-RICH PLASMA GEL (Type: EXPERIMENTAL): PLATELET RICH PLASMA GEL APPLICATION

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: ECT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have required at least 4 transfusions in the past 12 months~* PNH type III red blood cell (RBC) clone by flow cytometry of \>10%~* Lactate dehydrogenase (LDH) level \> 1.5 x upper limit of normal~* Platelet count \> 100,000/mm3~* Patient taking erythropoietin must be on a stable dose for at least 26 weeks~* Patient taking immunosuppressants must be on a stable dose for at least 26 weeks~* Patient taking corticosteroids must be on a stable dose for at least 4 weeks~* Patient taking coumadin must be at a stable INR for at least 4 weeks~* Patient taking iron supplements or folic acid must be on a stable dose for 4 weeks~* Willing and able to give written informed consent~* Must avoid conception~Exclusion Criteria:~* Mean hemoglobin level prior to transfusion over the previous 12 months is \>10.5 gm/dl~* Absolute neutrophil count \<500/ul~* Active bacterial infection~* Hereditary complement deficiency~* Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures within 30 days~* Pregnant, breast-feeding, or intending to conceive~* History of meningococcal disease~* History of bone marrow transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the MJGS Following Radiesse (+) Injection Into the Jawline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has right and left jawlines with moderate to severe volume/contour loss as determined by a live, masked evaluator.~2. Is at least 18 years of age.~3. Understands and accepts the obligation not to receive any other procedures below the orbital rim including the neck during participation in the study.~4. Understands and accepts the obligation and is logistically able to present for all scheduled study visits and meet all study requirements.~Exclusion Criteria:~1. Has ever been treated with silicone, PMMA (polymethyl methacrylate), fat injections, poly-L-lactic acid (PLLA; Sculptra®) or permanent dermal fillers below the orbital rim including the neck.~2. Has had surgery on the jawbone or has surgical permanent implant to the face or neck.~3. Has bruxism, masseter muscle hypertrophy or asymmetry of masseter muscles, active temporomandibular joint (TMJ) disease or disorder, or active periodontal disease.~4. Has any medical condition with the potential to interfere with the study or increase the risk of adverse events.~5. Has undergone oral surgery recently or plans to undergo oral surgery procedures during participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
- Control Group (Type: NO_INTERVENTION): The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients scheduled for bariatric surgery at Flagler Hospital will be included after written and informed consent.~Exclusion Criteria:~* Patients will be excluded from the study if they don't consent to participate in the study. Patients allergic to any of the study medication will be excluded. Patients with second or third degree heart block will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Balanced Anesthesia (Type: NO_INTERVENTION): Patients will receive balanced general anesthesia including volatile anesthetics and narcotics. This reflects our current clinical practice.
- NoNarc TIVA (Type: ACTIVE_COMPARATOR): Patients will receive narcotic free total intravenous anesthesia with Propofol, dexmedetomidine and ketamine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of L-arabinose on Intestinal Sucrase Activity in Man

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* healthy males~* BMI between 18.4-25 kg/m2~* age between 18 and 30~Exclusion Criteria:~* donation of blood 3 months before or during the study~* gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease (HIV or hepatitis)~* smoking~* consumption of more than 21 alcoholic drinks/week~* elite athletes~* on medication

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed cholangiocarcinoma.~* Radiographically measurable or evaluable disease per RECIST v1.1.~* Tumor assessment for FGF/FGFR gene alteration status.~* Documented disease progression after at least 1 line of prior systemic therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~* Life expectancy ≥ 12 weeks.~Exclusion Criteria:~* Prior receipt of a selective FGFR inhibitor.~* History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.~* Current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination.~* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report
- Cohort B Pemigatinib (Type: EXPERIMENTAL): Pemigatinibin subjects with other FGF/FGFR alterations
- Cohort C Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects negative for FGF/FGFR alteration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fesoterodine Flexible Dose Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overactive bladder symptoms for greater than or equal to 3 months.~* Mean urinary frequency of greater than or equal to 8 micturitions per 24 hours in bladder diary.~* Mean number of Urgency episodes greater than or equal to 3 per 24 hours in bladder diary.~Exclusion Criteria:~* Contraindication to fesoterodine (antimuscarinics).~* Known etiology of OAB (e.g., neurogenic, local urinary tract pathology).~* Previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline.~* Unable to follow the study procedures, including completion of self-administered bladder diary and patient reported outcome questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine (Double-Blind) (Type: EXPERIMENTAL): None
- Placebo (Double-Blind) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who completed induction studies A3921094 or A3921095 and were classified as not meeting clinical response criteria; OR~* Subjects who completed maintenance study A3921096 or who discontinued treatment early in Study A3921096 due to treatment failure.~Exclusion Criteria:~* Subjects who had a major protocol violation in Study A3921094, A3921095 or A3921096.~* Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.~* Subjects who have had surgery for ulcerative colitis or in the opinion of the investigator, are likely to require surgery for ulcerative colitis during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP-690,550 5 mg BID (Type: EXPERIMENTAL): 5 mg BID
- CP-690,550 10 mg BID (Type: EXPERIMENTAL): 10 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet the ICD indications~* Patients with Class III or IV heart failure.~* Patients receiving or who received a Medtronic CRT ICD within the previous 3 months.~* Patient must sign and date informed consent, and be 18 years of age or greater.~* Patient must be available for follow up visits, and be willing and able to comply with study protocol.~Exclusion Criteria:~* Patient with acute myocardial infarction (MI), coronary artery bypass graft surgery (CABG) or percutaneous coronary angioplasty (PTCA)/stent within the last month.~* Patient with a mechanical right heart valve.~* Patient with chronic (permanent) atrial arrhythmias.~* Patient with life expectancy of less than 12 months.~* Patient with status post heart transplant~* Patient undergoing kidney dialysis~* Patients enrolled in a concurrent study that may confound the results of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Provoked Craving Assessment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current cigarette smokers who have smoked regularly, and smoke more than 20 cigarettes per day on a regular basis for at least a year;~* Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history.~Exclusion Criteria:~* Any disease that may interfere with the absorption, metabolism or excretion of the study product.~* A medical condition that might jeopardise the safety of the subject or the validity of the study results. For example, recent myocardial infarction or cerebrovascular incident (within 12 weeks of the screening visit), phenylketonuria, unstable or worsening angina pectoris, Prinzmetals angina or severe cardiac arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Nicotine Polacrilex mint mini lozenge (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): mint mini lozenge with no active

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete